AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Cagrilintide research guide

Lipidated amylin analogue with amylin and calcitonin receptor activity

Cagrilintide identity, receptor studies and human trial evidence, with single-compound research kept separate from cagrilintide–semaglutide combinations.

AUS Peptide Supply editorial team
AM8330833

01 · Identity

What the name identifies

Cagrilintide is a lipidated peptide analogue of amylin, also called AM833 or 0833 in research records. Its development involved changes intended to support a longer-acting analogue. Receptor experiments describe activity at amylin and calcitonin receptors. CagriSema denotes a combination involving cagrilintide and semaglutide; it is not another name for cagrilintide alone.

02 · Evidence position

What the literature can support

The evidence includes receptor pharmacology and randomised human studies of specified formulations. Single-compound and combination trials answer different questions. Read the population, comparator, duration and endpoint beside each finding; neither type of trial establishes the identity or performance of a catalogue vial. The records below are selected primary studies, not a claim about the latest development phase.

03 · Study-level map

Evidence and its limits

Preclinical

Which receptor profile was measured?

A 2021 pharmacology study compared AM833 with other calcitonin-family agonists across receptor binding, activation and regulation assays. It characterised AM833 as an agonist at both amylin and calcitonin receptors.

Limit: An assay profile depends on the receptor system and endpoint. It does not make cagrilintide interchangeable with every amylin analogue or verify a supplier sample.

Human randomised

What did the single-compound trial examine?

The 2021 phase 2 trial followed 706 adults with overweight or obesity without diabetes over 26 weeks. Cagrilintide groups had greater mean body-weight reduction than placebo; gastrointestinal events and treatment discontinuations were also assessed.

Limit: The finding belongs to the specified clinical formulation, trial population and analysis. It is not a result for an APS research presentation.

Human randomised

How is the combination evidence different?

The 2025 REDEFINE 1 trial randomised 3,417 adults without diabetes to cagrilintide–semaglutide, either component alone or placebo. The combination produced greater mean body-weight reduction than placebo at 68 weeks, with more gastrointestinal adverse events.

Limit: Combination findings cannot be assigned to cagrilintide alone. Comparator, analysis method and tolerability remain part of the interpretation.

04 · Analytical context

Questions a batch record should answer

  1. 01Does the material specification identify cagrilintide and its relevant peptide modifications rather than only a broad amylin label?
  2. 02Is the stated vial amount supported by a quantitative result with its reporting basis, separately from chromatographic purity?
  3. 03Which sample and lot identifiers connect any supplied report to the material offered, and which requested properties were actually tested?

05 · Boundary conditions

What this record does not establish

  • A single-compound listing does not contain semaglutide unless that separate ingredient is explicitly specified.
  • The selected clinical studies do not establish equivalence between their formulations and independently supplied laboratory material.
  • No matching APS analytical report for the listed Cagrilintide formats was verified for this guide; purity, content and lot traceability must not be inferred from another supplier.

Sources checked

  1. 1.
    Development and structure–activity work on cagrilintide

    Kruse et al. — Journal of Medicinal Chemistry · 2021 · Primary study

  2. 2.
    AM833 pharmacology across calcitonin-family receptor assays

    Fletcher et al. — Journal of Pharmacology and Experimental Therapeutics · 2021 · Primary study

  3. 3.
    Cagrilintide monotherapy in a 26-week randomised trial

    Lau et al. — The Lancet · 2021 · Primary study

  4. 4.
    Coadministered cagrilintide and semaglutide: REDEFINE 1

    Garvey et al. — New England Journal of Medicine · 2025 · Primary study

  5. 5.
    0839 as a preclinical tool for studying amylin analogues

    Gabery et al. — Life Sciences · 2025 · Primary study

Continue through the topic